50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

Moderna completes FDA submission for use of COVID shot in adolescents, kids

Published 05/11/2022, 03:59 PM
Updated 05/12/2022, 12:20 AM
© Reuters. FILE PHOTO: A vial labelled "Moderna COVID-19 Vaccine" is seen in this illustration taken January 16, 2022. REUTERS/Dado Ruvic/Illustration/File Photo
MRNA
-

(Reuters) - Moderna (NASDAQ:MRNA) Inc has made all necessary submissions required by the U.S. Food & Drug Administration for emergency use authorization of its COVID-19 vaccine in adolescents and children, it said on Wednesday.

The company is seeking approval for the use of its vaccines in three distinct age groups - adolescents aged 12 to 17 years, children aged six to 11 and those between six years and six months. The submissions for all three groups were made on May 9, it said.

Although Moderna's vaccine is approved by the FDA for use in adults 18 years and older, its use in other age groups has hit a roadblock as U.S. regulators have sought more safety data.

Australia, Canada and the European Union though have approved the vaccine for use in six- to 17-year olds.

© Reuters. FILE PHOTO: A vial labelled

The company sought U.S. authorization of its COVID shot in children under the age of 6 in April.

An advisory panel of experts to the U.S. drug regulator will meet in June to review the request.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.